ÂÜÀòÂÒÂ×

Dr. King Lee is serving as the Executive Director of Regulatory Affairs at Brightech International and Vice President of Regulatory Affairs of Axella Research. Both companies have been jointly working on numerous projects since 2015. Prior to that, Dr. Lee was the Vice President of Regulatory and Clinical Affairs for Cornerstone Pharmaceuticals, Inc., a company that develops novel anticancer agents such as Altered Energy Metabolism-Directed (AEMD) compounds that affect tumor-specific pyruvate dehydrogenase complex (PDC), since 2004. Dr. Lee was also an independent consultant to a number of companies, including ExSAR Corporation and ZYWIE LCC, providing regulatory affairs services in the development of new products for the treatment of metabolic diseases such as Tay-Sachs disease and Gaucher’s Disease. Dr. Lee is also a consultant to Pars Pharmaceuticals, is a CRO providing various services to pharmaceutical companies. Previously, he was the Vice President of Regulatory Affairs for Acorda Therapeutics, Inc.